CISPLATIN- cisplatin injection, solution
Fresenius Kabi USA, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Fresenius Kabi USA, LLC
Three Corporate Drive
Lake Zurich, Illinois 60047
T 847-550-2300
T 888-391-6300
www.fresenius-kabi.com/us

August 30, 2023

IMPORTANT PRESCRIBING INFORMATION

Subject: Temporary Importation of CISplatin Injection to Address Drug Shortage

Dear Healthcare Professional,

Due to the critical shortage of CISplatin Injection in the U.S. market, Fresenius Kabi USA, LLC (Fresenius Kabi USA) is coordinating with the U.S. Food and Drug Administration (FDA) to increase availability of the drug. Fresenius Kabi USA has initiated temporary importation of CISplatin Injection BP (KEMOPLAT) 50 mg/50 mL into the U.S. market. This product is marketed in Europe and is manufactured in India and is not FDA-approved.

At this time, no other entity except Fresenius Kabi USA is authorized by the FDA to import or distribute Fresenius Kabi's CISplatin Injection in the U.S.

Effective immediately, and during this temporary period, Fresenius Kabi USA will distribute the following presentation of CISplatin Injection to address the critical shortage:

Product Name	Quantity	Description	U.S. NDC Number	Lot Number	Exp Date
CISplatin Injection BP† (KEMOPLAT) 50 mg/50 mL (1 mg/mL) †BP = British Pharmacopeia	1 amber single dose vial per carton	Clear, colorless to pale yellow solution. Each mL contains 1 mg Cisplatin and 9 mg sodium chloride in water for injection	65219-359-50	87230281A	05/2025

It is important to note the following:

- The imported product is labeled CISplatin Injection BP (KEMOPLAT) 50 mg/50 mL (1

mg/mL). BP stands for British Pharmacopeia and is not an acronym for an ingredient in the formulation. The BP provides quality standards for UK pharmaceutical substances and medicinal products.

- The carton labeling and container labeling do not include the warning statements, “Stop! Verify Drug Name and Dose!” or “CISplatin doses greater than 100 mg/m^2 once every 3 to 4 weeks are rarely used.” See U.S. package insert.
- The product is a single dose vial. Fresenius Kabi does NOT have extended stability data once the vial is punctured or information on withdrawing multiple doses.
- The imported product is a clear, colorless to pale yellow solution while the US product is a clear, colorless solution.
- Any barcodes on CISplatin Injection will not be appropriately recognized by scanning systems used in the United States and should NOT be used. Institutions should manually input the product into their systems to confirm that barcode systems do not provide incorrect information when the product is scanned. Alternative procedures should be followed to assure that the correct drug product is being prepared and administered to individual patients.
- In addition, the carton of the imported product does not include a product identifier as required under the Drug Supply Chain Security Act (DSCSA). Specifically, each package of product does not include the NDC, unique serial number, lot number, and expiration date in both human-readable form and a two-dimensional data matrix barcode.

Please ensure that staff and others within the institution who may be involved in the administration of CISplatin Injection receive a copy of this letter and review the information.

This communication and product information is available on the Fresenius Kabi USA website: https://www.fresenius-kabi.com/us/documents/CISplatin-DHCP-Letter.pdf as well as on the FDA Drug Shortage website http://www.fda.gov/Drugs/DrugSafety/DrugShortages/default.htm.

REPORTING ADVERSE EVENTS

To report adverse events experienced with the use of this product, call Fresenius Kabi USA Vigilance at 1-800-551-7176, Monday - Friday, between the hours of 8 a.m. and 5 p.m. (CST), or e-mail adverse.events.USA@fresenius-kabi.com.

To report a product quality complaint with the use of this product, call 1-800-551-7176 or e-mail productcomplaint.USA@fresenius-kabi.com.

Fresenius Kabi USA CONTACT NUMBERS: Please use the following contact numbers as appropriate:

Reason To Call	Department	Number
ADE Reporting	Vigilance Department	1-800-551-7176
Clinical/Technical Info. Or Product Quality Complaint	Medical Affairs Department	
Product Availability & Ordering	Customer Service Department	1-888-386-1300

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by

regular mail or by fax.

- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form http://www.fda.gov/medwatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 (1-800-332-0178).

Sincerely,

Anthony Giessert, Ph.D.
Vice President, Quality Assurance
Fresenius Kabi USA, LLC

CISplatin Injection Product Labels

	U.S. FDA Approved Product	Imported Product†
Carton Label		
Vial Label		

Product Image		

†BP = British Pharmacopeia

CISplatin Injection Product and Prescribing Information Side-by-Side Comparison Table

	U.S. FDA Approved Product	**Imported Product**
Product Name	CISplatin Injection	CISplatin Injection BP (KEMOPLAT) (BP = British Pharmacopeia)
Active Ingredient	CISplatin	CISplatin
Available Strengths/Concentrations	50 mg/50 mL (1 mg/mL) 100 mg/100 mL (1 mg/mL) 200 mg/200 mL (1 mg/mL)	50 mg/50 mL (1 mg/mL)
Route of Administration	For Intravenous Use (must be further diluted prior to administration)	For I.V. Infusion After Dilution
Container	Amber multiple dose vial with 28 mm vial closure The container closure is not made with natural rubber latex.	Amber single dose vial with 20 mm vial closure The container closure is not made with natural rubber latex.
Product Description	Cisplatin Injection is a clear, colorless, sterile aqueous solution. Each 50 mL, 100 mL or 200 mL amber vial of Cisplatin Injection contains: 1 mg/mL cisplatin, 9 mg/mL sodium chloride, hydrochloric acid and/or sodium hydroxide to adjust pH, and water for injection to a final volume of 50 mL, 100 mL or 200 mL, respectively. The pH range of Cisplatin Injection is 3.8 to 5.9.	Kemoplat is a clear, colourless to pale yellow solution. KEMOPLAT is a sterile solution of Cisplatin BP 1.0mg/ml (50ml pack), sodium chloride BP 9mg/ml in Water for Injections BP.

Storage and Handling	Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not refrigerate. Protect from light. ***Stability*** Cisplatin is a sterile, multiple dose vial without preservatives. **Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not refrigerate. Protect unopened container from light.** The cisplatin remaining in the amber vial following initial entry is stable for 28 days protected from light or for 7 days under fluorescent room light.	Store at a temperature between 15°C - 25°C. Protect from light. Do not refrigerate.
Indications	Cisplatin Injection is indicated as therapy to be employed as follows: ***Metastatic Testicular Tumors*** In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. ***Metastatic Ovarian Tumors*** In established combination therapy with other approved chemotherapeutic agents in patients with meta static ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard	KEMOPLAT is indicated for following indications: **Metastatic Testicular Cancer**: In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radio therapeutic procedures. **Metastatic Ovarian Cancer**: In established combination therapy with other approved chemotherapeutic agents KEMOPLAT is used in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radio therapeutic procedures. Also as a single agent, it is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously

	chemotherapy who have not previously received Cisplatin Injection therapy. ***Advanced Bladder Cancer*** Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.	received cisplatin therapy. **Advanced Bladder Cancer**: Cisplatin is indicated as a single agent for patients with transitional cell bladder cancer, which is no longer amenable to local treatments such as surgery and/or radiotherapy.
Contraindications	Cisplatin is contraindicated in patients with pre-existing renal impairment. Cisplatin should not be employed in myelosuppressed patients, or in patients with hearing impairment. Cisplatin is contraindicated in patients with a history of allergic reactions to cisplatin or other platinum-containing compounds.	Use of cisplatin is contraindicated in patients with a history of hypersensitivity to cisplatin or other platinum containing compounds. Cisplatin should not be used in patients with preexisting renal impairment, myelosuppressed patients or patients with hearing impairment.
Dosage and Administration	Cisplatin is administered by slow intravenous infusion. CISPLATIN SHOULD NOT BE GIVEN BY RAPID INTRAVENOUS INJECTION. **Note: Needles or intravenous sets containing aluminum parts that may come in contact with cisplatin should not be used for preparation or administration. Aluminum reacts with cisplatin, causing precipitate formation and a loss of potency.** ***Metastatic Testicular Tumors*** The usual cisplatin dose for the treatment of testicular cancer in combination with other approved chemo therapeutic agents is 20 mg/m^2 IV daily for 5 days per cycle. ***Metastatic Ovarian Tumors*** The usual cisplatin	**Metastatic Testicular Cancer:** The usual dose for the treatment of testicular cancer in combination with other approved chemotherapeutic agents is 20 mg/m^2 I.V. daily for 5 days per cycle. **Metastatic Ovarian Cancer:** The usual cisplatin dose for the treatment of metastatic ovarian cancer in combination with cyclophosphamide is 75-100 mg/m^2 I.V. per cycle once every 4 weeks, (Day 1). As a single agent cisplatin should be administered as 100 mg/m^2/cycle IV every 4 weeks. **Advanced Bladder Cancer:** cisplatin should be administered as a single agent at a dose of 50-70 mg/m^2 I.V. per cycle once

	dose for the treatment of metastatic ovarian tumors in combination with cyclophosphamide is 75 to 100 mg/m^2 IV per cycle once every 4 weeks (DAY 1). The dose of cyclophosphamide when used in combination with cisplatin is 600 mg/m^2 IV once every 4 weeks (DAY 1). For directions for the administration of cyclo-phosphamide, refer to the cyclophosphamide package insert. In combination therapy, cisplatin and cyclophosphamide are administered sequentially. As a single agent, cisplatin should be administered at a dose of 100 mg/m^2 IV per cycle once every 4 weeks. ***Advanced Bladder Cancer*** Cisplatin should be administered as a single agent at a dose of 50 to 70 mg/m^2 IV per cycle once every 3 to 4 weeks depending on the extent of prior exposure to radiation therapy and/or prior chemotherapy. For heavily pre-treated patients an initial dose of 50 mg/m^2 per cycle repeated every 4 weeks is recommended. ***All Patients*** Pretreatment hydration with 1 to 2 liters of fluid infused for 8 to 12 hours prior to a cisplatin dose is recommended. The drug is then diluted in 2 liters of 5% Dextrose in 1/2 or 1/3 normal saline containing 37.5 g of mannitol, and infused over a 6- to 8-hour period. If diluted solution is not to be used within 6 hours, protect solution from light. Do not dilute cisplatin in just 5% Dextrose Injection. Adequate	every 3 to 4 weeks depending on the extent of prior exposure to radiation therapy and/or prior chemotherapy. For heavily pretreated patients an initial dose of 50 mg/m^2 per cycle repeated every four weeks is recommended. a) Pre Treatment Hydration: Patients should be adequately hydrated before and for 24 hrs. after KEMOPLAT administration in order to induce diuresis and minimize nephrotoxicity. Hydration may be achieved either by I.V. infusion of 2 liters of 0.9% sodium chloride or dextrose saline (Dextrose 5% in one fifth normal saline (0.18% Sodium chloride injection) over a 6-12 hr. period. During the last 30 minutes of the pre treatment hydration or after the hydration, 375 ml of 20% mannitol injection may be administered via a side arm drip. b) Preparation of KEMOPLAT infusion: KEMOPLAT should be added to 2 liters of 0.9% sodium chloride injection or Dextrose-Saline solution. c) Treatment: Following pre-hydration, KEMOPLAT infusion is administered over 1-2 hrs. A longer infusion time of 6-8 hrs may decrease gastrointestinal and renal toxicities. d) Post Treatment Hydration It is recommended that I.V. hydration should continue after treatment with

	hydration and urinary output must be maintained during the following 24 hours. A repeat course of cisplatin should not be given until the serum creatinine is below 1.5 mg/100 mL, and/or the BUN is below 25 mg/100 mL. A repeat course should not be given until circulating blood elements are at an acceptable level (platelets $\geq$100,000/mm^3, WBC $\geq$4,000/mm^3). Subsequent doses of cisplatin should not be given until an audiometric analysis indicates that auditory acuity is within normal limits. ***Preparation of Intravenous Solutions*** The aqueous solution should be used intravenously only and should be administered by IV infusion over a 6- to 8-hour period (see **DOSAGE AND ADMINISTRATION**). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. **NOTE TO PHARMACIST:** Exercise caution to prevent inadvertent cisplatin overdosage. Please call prescriber if dose is greater than 100 mg/m^2 per cycle. Aluminum and flip-off seal of vial have been imprinted with the following statement: **CALL DR. IF DOSE >100 MG/M^2/CYCLE.**	administration of 2 liters 0.9% sodium chloride IV infusion or Dextrose-saline over a period of 6-12 hours. NOTE: Since aluminum reacts with and inactivates cisplatin, it is important not to use needles or other equipment that contain aluminum while preparing or administering KEMOPLAT.

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Cisplatin Injection 50 mL Carton Panel

50mg/50 ml

Rx

Cisplatin

Injection BP

1 mg/ml

KEMOPLAT

Single Dose Vial

50 ml



PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Cisplatin Injection 50 mL Vial Label

50mg/50 ml

Rx

Cisplatin Injection BP

1 mg /ml

Kemoplat

Single Dose Vial

50 ml



CISPLATIN

cisplatin injection, solution

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	**Item Code (Source)**	NDC:65219-359
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**
CISPLATIN (UNII: Q20Q21Q62J) (CISPLATIN - UNII:Q20Q21Q62J)	CISPLATIN	1 mg in 1 mL

Inactive Ingredients	
Ingredient Name	**Strength**
SODIUM CHLORIDE (UNII: 451W47IQ8X)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	
WATER (UNII: 059QF0KO0R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:65219-359-50	1 in 1 CARTON	09/01/2023	02/22/2024
1		50 mL in 1 VIAL; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Unapproved drug for use in drug shortage		09/01/2023	

Labeler - Fresenius Kabi USA, LLC (013547657)

Establishment

Name	Address	ID/FEI	Business Operations
Fresenius Kabi Oncology Limited		915786944	API MANUFACTURE(65219-359)

Revised: 2/2024 Fresenius Kabi USA, LLC